Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
NCT ID: NCT03109457
Last Updated: 2020-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2017-09-06
2018-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt
NCT05047146
Plasma MicroRNA for Prediction of Hepatocellular Carcinoma
NCT05449847
Serum Visfatin and Serum Vaspin in Patients With Hepatocellular Carcinoma on Top of Liver Cirrhosis
NCT04763707
Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma
NCT05327907
Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits
NCT01937286
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. OSCC specimens. Histological diagnosis of H\&E stained sections will be performed according to World health organisation (WHO) guidelines by 2 independent pathologists.
2. Normal oral mucosa specimens (control).
outcome: I) Immunohistochemical detection of Hepatitis C core antigen (Hep C cAg) : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining. Staining procedure using an automated system Ventana Benchmark. The four µm thick paraffin embedded tissue sections will be deparaffinized in three changes of xylene then microwaved for antigen retrieval. The slides will be incubated with primary antibody overnight in the humidity chamber at room temperature. Then, the slides will be incubated with secondary antibody. The peroxidase activity will be made visible with diaminobenzidine. Finally, counterstaining will be obtained using Mayer's hematoxylin.
The immunostained sections will be examined using analyzer computer system (Germany).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral squamous cell carcinoma
Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.
Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining.
oral squamous cell carcinoma
Histological diagnosis of H\&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
Control
Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.
Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining.
oral squamous cell carcinoma
Histological diagnosis of H\&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
oral squamous cell carcinoma
Histological diagnosis of H\&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Presence of oral cavity cancer (including oral tongue, floor of mouth, gingiva, lips, buccal mucosa)
3. Absence of recurrent head and neck cancer
4. Absence of previous oncologic therapy;
5. Histological-proven squamous cell carcinoma.
\-
Exclusion Criteria
\-
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Noura Kamal Aly
assistant lecturer, Oral and Maxillofacial pathology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nora Ali, Msc
Role: PRINCIPAL_INVESTIGATOR
Assistant Lecturer at Oral and Maxillofacial pathology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr ALini Hospital
Giza, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEBD-CU-2017-04-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.